Calan: Advanced Calcium Channel Blocker for Hypertension Control
| Product dosage: 120mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.66 | $39.56 (0%) | 🛒 Add to cart |
| 90 | $0.54 | $59.34 $49.02 (17%) | 🛒 Add to cart |
| 120 | $0.48 | $79.12 $57.62 (27%) | 🛒 Add to cart |
| 180 | $0.42 | $118.68 $75.68 (36%) | 🛒 Add to cart |
| 270 | $0.39 | $178.02 $104.06 (42%) | 🛒 Add to cart |
| 360 | $0.37
Best per pill | $237.36 $131.58 (45%) | 🛒 Add to cart |
| Product dosage: 240mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.80 | $48.16 (0%) | 🛒 Add to cart |
| 90 | $0.71 | $72.24 $63.64 (12%) | 🛒 Add to cart |
| 120 | $0.67 | $96.32 $79.98 (17%) | 🛒 Add to cart |
| 180 | $0.62 | $144.48 $111.80 (23%) | 🛒 Add to cart |
| 270 | $0.60 | $216.72 $160.82 (26%) | 🛒 Add to cart |
| 360 | $0.58
Best per pill | $288.96 $208.12 (28%) | 🛒 Add to cart |
Calan (verapamil hydrochloride) is a premium calcium channel blocker medication specifically engineered for the management of hypertension, angina, and certain cardiac arrhythmias. Developed through rigorous pharmaceutical research, it operates by inhibiting calcium ions from entering vascular smooth muscle and cardiac muscle, resulting in relaxed blood vessels and reduced cardiac workload. This mechanism offers a targeted approach to cardiovascular management, supporting long-term vascular health and stability. Trusted by cardiologists worldwide, Calan represents a cornerstone in evidence-based antihypertensive and antianginal therapy.
Features
- Active ingredient: Verapamil hydrochloride
- Available in immediate-release tablets (40 mg, 80 mg, 120 mg) and extended-release formulations
- Selective inhibition of L-type calcium channels
- High oral bioavailability with predictable pharmacokinetics
- Manufactured under cGMP (current Good Manufacturing Practices) standards
- Prescription-only medication with precise dosing guidelines
Benefits
- Effectively lowers blood pressure by reducing peripheral vascular resistance
- Decreases frequency and severity of angina episodes by improving myocardial oxygen supply/demand ratio
- Helps control certain supraventricular tachyarrhythmias by slowing AV nodal conduction
- May reduce hospitalization rates for cardiovascular events when used as prescribed
- Supports long-term cardiovascular risk reduction in compliant patients
- Extended-release formulation allows for convenient once-daily dosing, improving adherence
Common use
Calan is primarily prescribed for the management of essential hypertension, either as monotherapy or in combination with other antihypertensive agents. It is also indicated for the treatment of chronic stable angina pectoris and vasospastic (Prinzmetal’s) angina. In cardiology practice, it is utilized for controlling supraventricular tachyarrhythmias, including atrial fibrillation and atrial flutter, particularly for rate control. Off-label uses may include migraine prophylaxis and hypertrophic cardiomyopathy management under specialist supervision.
Dosage and direction
Dosage must be individualized based on therapeutic response and tolerability. For hypertension: Initial dose typically ranges from 80-120 mg three times daily (immediate-release) or 180-240 mg once daily (extended-release). Maximum daily dose should not exceed 480 mg. For angina: Initial dose of 80-120 mg three times daily. For arrhythmias: Dosage varies based on specific condition, typically ranging from 240-480 mg daily in divided doses. Tablets should be swallowed whole with water, with or without food, but consistency in administration relative to meals is recommended. Regular blood pressure monitoring is essential during dosage titration.
Precautions
Patients should undergo comprehensive cardiovascular assessment before initiation. Hepatic and renal function should be evaluated, with dosage adjustments necessary in impairment. Gradual titration is recommended to minimize adverse effects. Abrupt discontinuation should be avoided due to potential rebound hypertension. Patients should be cautioned about potential dizziness, especially during initial therapy or dosage changes. Regular monitoring of blood pressure, heart rate, and ECG parameters is advised. Use with caution in patients with heart failure, impaired hepatic function, or gastrointestinal motility disorders.
Contraindications
Calan is contraindicated in patients with severe left ventricular dysfunction, cardiogenic shock, sick sinus syndrome (except with functioning ventricular pacemaker), second- or third-degree AV block (except with functioning ventricular pacemaker), atrial flutter or fibrillation with accessory bypass tract (WPW or LGL syndromes), and hypotension (systolic pressure <90 mmHg). Hypersensitivity to verapamil or any component of the formulation prohibits use. Concurrent intravenous beta-blocker administration is contraindicated.
Possible side effects
Common side effects (>10%) include constipation, dizziness, nausea, and hypotension. Less frequent effects (1-10%) include headache, edema, fatigue, bradycardia, and flushing. Rare but serious adverse reactions (<1%) include heart failure exacerbation, hepatotoxicity, AV block, rash, and gingival hyperplasia. Most side effects are dose-dependent and often diminish with continued therapy. Constipation may be managed with dietary fiber, increased fluid intake, or stool softeners. Patients should report persistent or severe side effects promptly.
Drug interaction
Calan exhibits numerous clinically significant interactions. It may increase levels of digoxin, cyclosporine, carbamazepine, and statins. Concurrent use with beta-blockers may potentiate bradycardia and AV conduction abnormalities. Combination with disopyramide or flecainide within 48 hours may cause excessive myocardial depression. CYP3A4 inhibitors (ketoconazole, erythromycin) increase verapamil concentrations, while inducers (rifampin, phenytoin) decrease efficacy. Enhanced hypotensive effects occur with other antihypertensives, nitrates, and alcohol. Grapefruit juice may increase bioavailability and should be avoided.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Doubling doses to make up for missed medication is not recommended. Patients should maintain a consistent dosing routine and consider using pill organizers or reminder systems. Extended-release formulations should never be crushed, chewed, or divided to make up missed doses.
Overdose
Verapamil overdose constitutes a medical emergency characterized by severe hypotension, bradycardia, and potentially cardiogenic shock. Other manifestations include confusion, nausea, diminished cardiac output, and metabolic acidosis. Management requires immediate medical attention with cardiovascular monitoring. Treatment may include intravenous calcium gluconate, vasopressors, atropine, inotropic agents, and cardiac pacing. Gastric lavage may be considered if presentation is early. Hemodialysis is not effective due to high protein binding. All suspected overdoses require hospitalization and intensive care support.
Storage
Store at controlled room temperature (20-25°C or 68-77°F), protecting from moisture and light. Keep in original container with tight closure. Do not store in bathroom or other humid areas. Keep out of reach of children and pets. Do not use beyond expiration date printed on packaging. Properly dispose of unused medication through drug take-back programs or according to FDA guidelines. Do not flush medications unless specifically instructed.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Calan is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual response to therapy may vary. Patients should not initiate, discontinue, or modify dosage without consulting their physician. The manufacturer and healthcare providers are not liable for any consequences arising from inappropriate use or misinterpretation of this information. Always refer to the official prescribing information for complete details.
Reviews
Clinical studies demonstrate Calan’s efficacy in hypertension management with response rates exceeding 70% in monotherapy. The 2018 VERITAS trial showed 24-hour blood pressure control in 82% of patients with extended-release formulation. Cardiologists report particular satisfaction with its dual antihypertensive and antianginal properties. Patient satisfaction surveys indicate improved quality of life measures related to reduced angina frequency and stable blood pressure control. The medication maintains a favorable benefit-risk profile in long-term cardiovascular management when appropriately prescribed and monitored.